Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00970502 · OUTCOME

Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer · Source last updated 2017-04-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
1 year

What was measured

At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates.

Groups in this outcome

Erlotinib + Celecoxib

Recommended dose of celecoxib was 400mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Erlotinib + Celecoxib15

Reported measurements

locoregional control
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib + Celecoxib60Not reportedNot reportedNot reportedNot reported
progress-free survival
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib + Celecoxib37Not reportedNot reportedNot reportedNot reported
overall survival rates
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib + Celecoxib55Not reportedNot reportedNot reportedNot reported
long term toxicity
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib + Celecoxib0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        60
    title
    locoregional control
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        37
    title
    progress-free survival
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        55
    title
    overall survival rates
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    long term toxicity
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates.
groups
  1. description
    Recommended dose of celecoxib was 400mg
    id
    OG000
    title
    Erlotinib + Celecoxib
param Type
NUMBER
reporting Status
POSTED
time Frame
1 year
title
Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice